Over the past decade chemerin, that was initially identified as a potent chemoattractant in different immune cells with pivotal roles in both innate and adaptive immunity, has increasingly emerged as a biomarker characterizing inflammatory and metabolic phenotypes, and linking low-grade inflammation with metabolic disorders (Helfer and Wu, 2018; Eichelmann et al., 2019; Koelman et al., 2021), having been proposed as an early marker of chronic subclinical inflammation (Koelman et al., 2021). This evidence concerns the gene RARRES2 and metabolic disease.